FLUPHENAZINE may increase the sedative activities of Rotigotine.


lidocaine may increase the sedative activities of pramipexole.


Tapentadol may increase the sedative activities of METYROSINE.


Ramelteon may increase the sedative activities of ropinirole.


procaine may increase the sedative activities of METYROSINE.


chloral hydrate may increase the sedative activities of METYROSINE.


temazepam may increase the sedative activities of Rotigotine.


triflupromazine may increase the sedative activities of pramipexole.


CHLOROPROCAINE may increase the sedative activities of pramipexole.


tiapride may increase the sedative activities of Rotigotine.


Oxetacaine may increase the sedative activities of ropinirole.


ethyl loflazepate may increase the sedative activities of ropinirole.


doxepin may increase the sedative activities of Rotigotine.


butamben may increase the sedative activities of ropinirole.


Oxybuprocaine may increase the sedative activities of ropinirole.


desipramine may increase the sedative activities of METYROSINE.


risperidone may increase the sedative activities of ropinirole.


etizolam may increase the sedative activities of Rotigotine.


fluvoxamine may increase the sedative activities of pramipexole.


bromazepam may increase the sedative activities of METYROSINE.


REMIFENTANIL may increase the sedative activities of Rotigotine.


TRICHLOROETHYLENE may increase the sedative activities of METYROSINE.


flurazepam may increase the sedative activities of pramipexole.


clonidine may increase the sedative activities of Rotigotine.


cyclobenzaprine may increase the sedative activities of ropinirole.


thiopental may increase the sedative activities of Rotigotine.


flunitrazepam may increase the sedative activities of pramipexole.


ethyl loflazepate may increase the sedative activities of Rotigotine.


Iloperidone may increase the sedative activities of pramipexole.


ketamine may increase the sedative activities of Rotigotine.


DIMENHYDRINATE may increase the sedative activities of Rotigotine.


methocarbamol may increase the sedative activities of ropinirole.


Ziprasidone may increase the sedative activities of ropinirole.


pentazocine may increase the sedative activities of METYROSINE.


estazolam may increase the sedative activities of ropinirole.


TRICHLOROETHYLENE may increase the sedative activities of Rotigotine.


butorphanol may increase the sedative activities of ropinirole.


zolpidem may increase the sedative activities of ropinirole.


chlorzoxazone may increase the sedative activities of ropinirole.


Methadyl acetate may increase the sedative activities of METYROSINE.


ethyl loflazepate may increase the sedative activities of pramipexole.


Retigabine may increase the sedative activities of METYROSINE.


doxylamine may increase the sedative activities of ropinirole.


Tasimelteon may increase the sedative activities of Rotigotine.


hydroxyzine may increase the sedative activities of METYROSINE.


methocarbamol may increase the sedative activities of pramipexole.


ethotoin may increase the sedative activities of pramipexole.


efavirenz may increase the sedative activities of pramipexole.


zonisamide may increase the sedative activities of ropinirole.


carisoprodol may increase the sedative activities of METYROSINE.


prilocaine may increase the sedative activities of pramipexole.


reserpine may increase the sedative activities of pramipexole.


promazine may increase the sedative activities of METYROSINE.


benzyl alcohol may increase the sedative activities of METYROSINE.


thiopental may increase the sedative activities of ropinirole.


scopolamine may increase the sedative activities of Rotigotine.


levodopa may increase the sedative activities of METYROSINE.


enflurane may increase the sedative activities of METYROSINE.


propofol may increase the sedative activities of Rotigotine.


levodopa may increase the sedative activities of ropinirole.


triprolidine may increase the sedative activities of Rotigotine.


nitrous oxide may increase the sedative activities of ropinirole.


Hexobarbital may increase the sedative activities of pramipexole.


alprazolam may increase the sedative activities of Rotigotine.


lorazepam may increase the sedative activities of Rotigotine.


felbamate may increase the sedative activities of METYROSINE.


cocaine may increase the sedative activities of Rotigotine.


Zuclopenthixol may increase the sedative activities of Rotigotine.


TETRABENAZINE may increase the sedative activities of Rotigotine.


Melatonin may increase the sedative activities of ropinirole.


doxylamine may increase the sedative activities of pramipexole.


dibucaine may increase the sedative activities of Rotigotine.


REMIFENTANIL may increase the sedative activities of pramipexole.


Ethylmorphine may increase the sedative activities of METYROSINE.


triazolam may increase the sedative activities of METYROSINE.


phenobarbital may increase the sedative activities of METYROSINE.


butorphanol may increase the sedative activities of Rotigotine.


DIMENHYDRINATE may increase the sedative activities of METYROSINE.


cocaine may increase the sedative activities of pramipexole.


Aripiprazole may increase the sedative activities of pramipexole.


Aceprometazine may increase the sedative activities of METYROSINE.


trifluoperazine may increase the sedative activities of ropinirole.


PARALDEHYDE may increase the sedative activities of ropinirole.


nitrous oxide may increase the sedative activities of METYROSINE.


pentobarbital may increase the sedative activities of pramipexole.


bromazepam may increase the sedative activities of ropinirole.


Fluspirilene may increase the sedative activities of Rotigotine.


Etomidate may increase the sedative activities of Rotigotine.


chlorpheniramine may increase the sedative activities of ropinirole.


morphine may increase the sedative activities of pramipexole.


ethosuximide may increase the sedative activities of Rotigotine.


halothane may increase the sedative activities of ropinirole.


carbamazepine may increase the sedative activities of pramipexole.


Eszopiclone may increase the sedative activities of pramipexole.


codeine may increase the sedative activities of pramipexole.


clozapine may increase the sedative activities of pramipexole.


pentazocine may increase the sedative activities of ropinirole.


VORTIOXETINE may increase the sedative activities of ropinirole.


Levocetirizine may increase the sedative activities of ropinirole.


Levetiracetam may increase the sedative activities of ropinirole.


baclofen may increase the sedative activities of Rotigotine.


procaine may increase the sedative activities of Rotigotine.


butabarbital may increase the sedative activities of pramipexole.


haloperidol may increase the sedative activities of METYROSINE.


METHOHEXITAL may increase the sedative activities of METYROSINE.


Tolcapone may increase the sedative activities of ropinirole.


tetracaine may increase the sedative activities of ropinirole.


carisoprodol may increase the sedative activities of Rotigotine.


trazodone may increase the sedative activities of pramipexole.


zopiclone may increase the sedative activities of Rotigotine.


Oxetacaine may increase the sedative activities of METYROSINE.


levorphanol may increase the sedative activities of Rotigotine.


propofol may increase the sedative activities of pramipexole.


Tolcapone may increase the sedative activities of Rotigotine.


amoxapine may increase the sedative activities of ropinirole.


Flibanserin may increase the sedative activities of pramipexole.


Dexbrompheniramine may increase the sedative activities of Rotigotine.


MELPERONE may increase the sedative activities of METYROSINE.


PARALDEHYDE may increase the sedative activities of METYROSINE.


thioridazine may increase the sedative activities of ropinirole.


pentazocine may increase the sedative activities of pramipexole.


DIPHENOXYLATE may increase the sedative activities of ropinirole.


butorphanol may increase the sedative activities of METYROSINE.


chlorzoxazone may increase the sedative activities of METYROSINE.


mesoridazine may increase the sedative activities of Rotigotine.


DESFLURANE may increase the sedative activities of pramipexole.


baclofen may increase the sedative activities of ropinirole.


Ethylmorphine may increase the sedative activities of ropinirole.


sevoflurane may increase the sedative activities of METYROSINE.


CHLOROPROCAINE may increase the sedative activities of Rotigotine.


thalidomide may increase the sedative activities of pramipexole.


tranylcypromine may increase the sedative activities of pramipexole.


MELPERONE may increase the sedative activities of ropinirole.


triflupromazine may increase the sedative activities of Rotigotine.


zolpidem may increase the sedative activities of METYROSINE.


Ziprasidone may increase the sedative activities of Rotigotine.


topiramate may increase the sedative activities of pramipexole.


secobarbital may increase the sedative activities of ropinirole.


Fosphenytoin may increase the sedative activities of pramipexole.


Levobupivacaine may increase the sedative activities of METYROSINE.


Aceprometazine may increase the sedative activities of ropinirole.


Tapentadol may increase the sedative activities of Rotigotine.


buspirone may increase the sedative activities of Rotigotine.


phenobarbital may increase the sedative activities of ropinirole.


clorazepate may increase the sedative activities of pramipexole.


tiapride may increase the sedative activities of METYROSINE.


loratadine may increase the sedative activities of ropinirole.


nortriptyline may increase the sedative activities of ropinirole.


fludiazepam may increase the sedative activities of pramipexole.


SUFENTANIL may increase the sedative activities of METYROSINE.


oxycodone may increase the sedative activities of ropinirole.


ketamine may increase the sedative activities of METYROSINE.


protriptyline may increase the sedative activities of Rotigotine.


Ramelteon may increase the sedative activities of Rotigotine.


ondansetron may increase the sedative activities of ropinirole.


Ethylmorphine may increase the sedative activities of pramipexole.


Ketobemidone may increase the sedative activities of Rotigotine.


thiamylal may increase the sedative activities of pramipexole.


buprenorphine may increase the sedative activities of Rotigotine.


orphenadrine may increase the sedative activities of METYROSINE.


tiagabine may increase the sedative activities of Rotigotine.


nortriptyline may increase the sedative activities of pramipexole.


amisulpride may increase the sedative activities of pramipexole.


ethanol may increase the sedative activities of METYROSINE.


propoxyphene may increase the sedative activities of pramipexole.


Fosphenytoin may increase the sedative activities of METYROSINE.


SERTINDOLE may increase the sedative activities of pramipexole.


triprolidine may increase the sedative activities of METYROSINE.


meperidine may increase the sedative activities of Rotigotine.


amoxapine may increase the sedative activities of METYROSINE.


DIHYDROCODEINE may increase the sedative activities of ropinirole.


Propoxycaine may increase the sedative activities of Rotigotine.


reserpine may increase the sedative activities of METYROSINE.


secobarbital may increase the sedative activities of pramipexole.


alprazolam may increase the sedative activities of METYROSINE.


nalbuphine may increase the sedative activities of METYROSINE.


butabarbital may increase the sedative activities of METYROSINE.


Levomepromazine may increase the sedative activities of ropinirole.


maprotiline may increase the sedative activities of METYROSINE.


tiagabine may increase the sedative activities of METYROSINE.


fexofenadine may increase the sedative activities of METYROSINE.


DIHYDROCODEINE may increase the sedative activities of METYROSINE.


lidocaine may increase the sedative activities of METYROSINE.


buspirone may increase the sedative activities of ropinirole.


doxylamine may increase the sedative activities of Rotigotine.


haloperidol may increase the sedative activities of Rotigotine.


Ramelteon may increase the sedative activities of pramipexole.


thalidomide may increase the sedative activities of Rotigotine.


perphenazine may increase the sedative activities of METYROSINE.


ketamine may increase the sedative activities of ropinirole.


enflurane may increase the sedative activities of Rotigotine.


Remoxipride may increase the sedative activities of pramipexole.


Perospirone may increase the sedative activities of ropinirole.


bupivacaine may increase the sedative activities of ropinirole.


flunarizine may increase the sedative activities of METYROSINE.


HEROIN may increase the sedative activities of Rotigotine.


ALFENTANIL may increase the sedative activities of ropinirole.


DIHYDROCODEINE may increase the sedative activities of Rotigotine.


MELPERONE may increase the sedative activities of pramipexole.


prochlorperazine may increase the sedative activities of ropinirole.


promethazine may increase the sedative activities of Rotigotine.


ethanol may increase the sedative activities of Rotigotine.


glutethimide may increase the sedative activities of Rotigotine.


Nabilone may increase the sedative activities of ropinirole.


loratadine may increase the sedative activities of METYROSINE.


thiamylal may increase the sedative activities of Rotigotine.


quazepam may increase the sedative activities of ropinirole.


Pipamperone may increase the sedative activities of Rotigotine.


chlorzoxazone may increase the sedative activities of pramipexole.


phenytoin may increase the sedative activities of ropinirole.


Fencamfamin may increase the sedative activities of ropinirole.


Agomelatine may increase the sedative activities of Rotigotine.


chlorprothixene may increase the sedative activities of ropinirole.


GUANFACINE may increase the sedative activities of ropinirole.


chlorpheniramine may increase the sedative activities of pramipexole.


Pregabalin may increase the sedative activities of pramipexole.


ethchlorvynol may increase the sedative activities of Rotigotine.


Sodium oxybate may increase the sedative activities of Rotigotine.


oxymorphone may increase the sedative activities of Rotigotine.


dantrolene may increase the sedative activities of pramipexole.


Flibanserin may increase the sedative activities of ropinirole.


buspirone may increase the sedative activities of pramipexole.


trifluoperazine may increase the sedative activities of Rotigotine.


zaleplon may increase the sedative activities of METYROSINE.


dibucaine may increase the sedative activities of ropinirole.


isoflurane may increase the sedative activities of pramipexole.


sevoflurane may increase the sedative activities of ropinirole.


chloral hydrate may increase the sedative activities of ropinirole.


Pregabalin may increase the sedative activities of ropinirole.


Levobupivacaine may increase the sedative activities of ropinirole.


ondansetron may increase the sedative activities of Rotigotine.


Pomalidomide may increase the sedative activities of ropinirole.


ethosuximide may increase the sedative activities of pramipexole.


quazepam may increase the sedative activities of METYROSINE.


hydromorphone may increase the sedative activities of pramipexole.


triprolidine may increase the sedative activities of ropinirole.


perphenazine may increase the sedative activities of ropinirole.


ethanol may increase the sedative activities of ropinirole.


ALFENTANIL may increase the sedative activities of METYROSINE.


chlordiazepoxide may increase the sedative activities of pramipexole.


olanzapine may increase the sedative activities of ropinirole.


zopiclone may increase the sedative activities of METYROSINE.


thiothixene may increase the sedative activities of ropinirole.


Etidocaine may increase the sedative activities of Rotigotine.


zopiclone may increase the sedative activities of ropinirole.


reserpine may increase the sedative activities of ropinirole.


etizolam may increase the sedative activities of ropinirole.


midazolam may increase the sedative activities of METYROSINE.


Melatonin may increase the sedative activities of pramipexole.


butalbital may increase the sedative activities of ropinirole.


scopolamine may increase the sedative activities of ropinirole.


quazepam may increase the sedative activities of pramipexole.


VORTIOXETINE may increase the sedative activities of Rotigotine.


Etomidate may increase the sedative activities of METYROSINE.


secobarbital may increase the sedative activities of METYROSINE.


REMIFENTANIL may increase the sedative activities of ropinirole.


butamben may increase the sedative activities of pramipexole.


nitrous oxide may increase the sedative activities of Rotigotine.


Asenapine may increase the sedative activities of ropinirole.


zotepine may increase the sedative activities of pramipexole.


clemastine may increase the sedative activities of Rotigotine.


diphenhydramine may increase the sedative activities of pramipexole.


protriptyline may increase the sedative activities of METYROSINE.


METAXALONE may increase the sedative activities of ropinirole.


protriptyline may increase the sedative activities of ropinirole.


thalidomide may increase the sedative activities of ropinirole.


sevoflurane may increase the sedative activities of pramipexole.


chloral hydrate may increase the sedative activities of pramipexole.


prochlorperazine may increase the sedative activities of METYROSINE.


lithium ion may increase the sedative activities of METYROSINE.


Desloratadine may increase the sedative activities of pramipexole.


meperidine may increase the sedative activities of ropinirole.


Aripiprazole may increase the sedative activities of Rotigotine.


Olopatadine may increase the sedative activities of ropinirole.


HYDROCODONE may increase the sedative activities of ropinirole.


perphenazine may increase the sedative activities of pramipexole.


clemastine may increase the sedative activities of METYROSINE.


Mephobarbital may increase the sedative activities of METYROSINE.


Etidocaine may increase the sedative activities of ropinirole.


Mephobarbital may increase the sedative activities of ropinirole.


METHSUXIMIDE may increase the sedative activities of METYROSINE.


Fosphenytoin may increase the sedative activities of Rotigotine.


hydroxyzine may increase the sedative activities of Rotigotine.


flunitrazepam may increase the sedative activities of ropinirole.


STIRIPENTOL may increase the sedative activities of METYROSINE.


buprenorphine may increase the sedative activities of pramipexole.


VALPROIC ACID may increase the sedative activities of Rotigotine.


Asenapine may increase the sedative activities of pramipexole.


Fencamfamin may increase the sedative activities of METYROSINE.


FLUTICASONE PROPIONATE may increase the sedative activities of pramipexole.


diazepam may increase the sedative activities of Rotigotine.


VORTIOXETINE may increase the sedative activities of pramipexole.


doxepin may increase the sedative activities of pramipexole.


Zuclopenthixol may increase the sedative activities of METYROSINE.


primidone may increase the sedative activities of Rotigotine.


Hexobarbital may increase the sedative activities of ropinirole.


zaleplon may increase the sedative activities of ropinirole.


Flupentixol may increase the sedative activities of pramipexole.


proparacaine may increase the sedative activities of Rotigotine.


Ketobemidone may increase the sedative activities of pramipexole.


protriptyline may increase the sedative activities of pramipexole.


Levomepromazine may increase the sedative activities of Rotigotine.


Fluspirilene may increase the sedative activities of pramipexole.


zotepine may increase the sedative activities of Rotigotine.


desipramine may increase the sedative activities of ropinirole.


phenytoin may increase the sedative activities of METYROSINE.


meperidine may increase the sedative activities of pramipexole.


DEZOCINE may increase the sedative activities of pramipexole.


etizolam may increase the sedative activities of METYROSINE.


amisulpride may increase the sedative activities of METYROSINE.


Pramocaine may increase the sedative activities of ropinirole.


dyclonine may increase the sedative activities of ropinirole.


BREXPIPRAZOLE may increase the sedative activities of Rotigotine.


propoxyphene may increase the sedative activities of METYROSINE.


flunitrazepam may increase the sedative activities of METYROSINE.


levodopa may increase the sedative activities of Rotigotine.


Suvorexant may increase the sedative activities of pramipexole.


Halazepam may increase the sedative activities of ropinirole.


felbamate may increase the sedative activities of pramipexole.


mepivacaine may increase the sedative activities of Rotigotine.


thalidomide may increase the sedative activities of METYROSINE.


methocarbamol may increase the sedative activities of METYROSINE.


azelastine may increase the sedative activities of pramipexole.


maprotiline may increase the sedative activities of Rotigotine.


tetracaine may increase the sedative activities of METYROSINE.


methadone may increase the sedative activities of Rotigotine.


temazepam may increase the sedative activities of pramipexole.


tiagabine may increase the sedative activities of ropinirole.


MELPERONE may increase the sedative activities of Rotigotine.


alprazolam may increase the sedative activities of pramipexole.


amitriptyline may increase the sedative activities of Rotigotine.


METAXALONE may increase the sedative activities of METYROSINE.


Perospirone may increase the sedative activities of pramipexole.


FLUTICASONE PROPIONATE may increase the sedative activities of Rotigotine.


oxymorphone may increase the sedative activities of METYROSINE.


Fospropofol may increase the sedative activities of ropinirole.


SUFENTANIL may increase the sedative activities of pramipexole.


Tapentadol may increase the sedative activities of ropinirole.


METHSUXIMIDE may increase the sedative activities of ropinirole.


Pregabalin may increase the sedative activities of Rotigotine.


KETAZOLAM may increase the sedative activities of METYROSINE.


loxapine may increase the sedative activities of pramipexole.


oxazepam may increase the sedative activities of pramipexole.


Levocetirizine may increase the sedative activities of pramipexole.


desipramine may increase the sedative activities of Rotigotine.


chlormezanone may increase the sedative activities of Rotigotine.


butalbital may increase the sedative activities of pramipexole.


Fluspirilene may increase the sedative activities of ropinirole.


glutethimide may increase the sedative activities of pramipexole.


pimozide may increase the sedative activities of pramipexole.


amitriptyline may increase the sedative activities of pramipexole.


Suvorexant may increase the sedative activities of Rotigotine.


ethotoin may increase the sedative activities of Rotigotine.


Remoxipride may increase the sedative activities of METYROSINE.


butalbital may increase the sedative activities of Rotigotine.


fexofenadine may increase the sedative activities of ropinirole.


Nabilone may increase the sedative activities of METYROSINE.


CYPROHEPTADINE may increase the sedative activities of pramipexole.


promethazine may increase the sedative activities of ropinirole.


droperidol may increase the sedative activities of ropinirole.


chlordiazepoxide may increase the sedative activities of METYROSINE.


METHSUXIMIDE may increase the sedative activities of pramipexole.


REMIFENTANIL may increase the sedative activities of METYROSINE.


Levomepromazine may increase the sedative activities of METYROSINE.


Melatonin may increase the sedative activities of Rotigotine.


chlorprothixene may increase the sedative activities of Rotigotine.


cetirizine may increase the sedative activities of ropinirole.


prazepam may increase the sedative activities of METYROSINE.


benzocaine may increase the sedative activities of ropinirole.


DEXMEDETOMIDINE may increase the sedative activities of pramipexole.


azelastine may increase the sedative activities of Rotigotine.


Sodium oxybate may increase the sedative activities of ropinirole.


nalbuphine may increase the sedative activities of pramipexole.


dyclonine may increase the sedative activities of METYROSINE.


methoxyflurane may increase the sedative activities of METYROSINE.


tranylcypromine may increase the sedative activities of Rotigotine.


meclizine may increase the sedative activities of METYROSINE.


CYCLIZINE may increase the sedative activities of pramipexole.


MAGNESIUM SULFATE may increase the sedative activities of ropinirole.


chlorzoxazone may increase the sedative activities of Rotigotine.


halothane may increase the sedative activities of pramipexole.


Levocetirizine may increase the sedative activities of Rotigotine.


methadone may increase the sedative activities of ropinirole.


scopolamine may increase the sedative activities of METYROSINE.


Fluspirilene may increase the sedative activities of METYROSINE.


midazolam may increase the sedative activities of ropinirole.


loratadine may increase the sedative activities of Rotigotine.


mepivacaine may increase the sedative activities of ropinirole.


gabapentin may increase the sedative activities of ropinirole.


Pramocaine may increase the sedative activities of METYROSINE.


mesoridazine may increase the sedative activities of METYROSINE.


clomipramine may increase the sedative activities of METYROSINE.


tiapride may increase the sedative activities of ropinirole.


Olopatadine may increase the sedative activities of pramipexole.


Desloratadine may increase the sedative activities of Rotigotine.


Oxetacaine may increase the sedative activities of pramipexole.


Butethal may increase the sedative activities of METYROSINE.


oxymorphone may increase the sedative activities of ropinirole.


Methadyl acetate may increase the sedative activities of Rotigotine.


chlorprothixene may increase the sedative activities of pramipexole.


DIPHENOXYLATE may increase the sedative activities of METYROSINE.


fluvoxamine may increase the sedative activities of ropinirole.


prilocaine may increase the sedative activities of ropinirole.


TRICHLOROETHYLENE may increase the sedative activities of pramipexole.


clorazepate may increase the sedative activities of METYROSINE.


Oxybuprocaine may increase the sedative activities of pramipexole.


secobarbital may increase the sedative activities of Rotigotine.


chlormezanone may increase the sedative activities of METYROSINE.


clemastine may increase the sedative activities of ropinirole.


Ropivacaine may increase the sedative activities of pramipexole.


dyclonine may increase the sedative activities of Rotigotine.


Pizotifen may increase the sedative activities of Rotigotine.


meclizine may increase the sedative activities of Rotigotine.


Pizotifen may increase the sedative activities of METYROSINE.


Hexobarbital may increase the sedative activities of METYROSINE.


gabapentin may increase the sedative activities of Rotigotine.


Paliperidone may increase the sedative activities of ropinirole.


diazepam may increase the sedative activities of METYROSINE.


triazolam may increase the sedative activities of Rotigotine.


4-Hydroxybutanoic acid may increase the sedative activities of Rotigotine.


VALPROIC ACID may increase the sedative activities of METYROSINE.


KETAZOLAM may increase the sedative activities of ropinirole.


phenobarbital may increase the sedative activities of Rotigotine.


morphine may increase the sedative activities of ropinirole.


proparacaine may increase the sedative activities of METYROSINE.


Aripiprazole may increase the sedative activities of ropinirole.


primidone may increase the sedative activities of pramipexole.


procaine may increase the sedative activities of pramipexole.


cyclobenzaprine may increase the sedative activities of pramipexole.


nortriptyline may increase the sedative activities of METYROSINE.


brimonidine may increase the sedative activities of METYROSINE.


Pipotiazine may increase the sedative activities of pramipexole.


DIMENHYDRINATE may increase the sedative activities of pramipexole.


dantrolene may increase the sedative activities of METYROSINE.


Remoxipride may increase the sedative activities of ropinirole.


Propoxycaine may increase the sedative activities of ropinirole.


Fospropofol may increase the sedative activities of Rotigotine.


HEROIN may increase the sedative activities of ropinirole.


zotepine may increase the sedative activities of METYROSINE.


phenobarbital may increase the sedative activities of pramipexole.


phenytoin may increase the sedative activities of Rotigotine.


tiapride may increase the sedative activities of pramipexole.


Paliperidone may increase the sedative activities of Rotigotine.


Oxetacaine may increase the sedative activities of Rotigotine.


flurazepam may increase the sedative activities of METYROSINE.


benzocaine may increase the sedative activities of Rotigotine.


zolpidem may increase the sedative activities of pramipexole.


temazepam may increase the sedative activities of ropinirole.


levodopa may increase the sedative activities of pramipexole.


MAGNESIUM SULFATE may increase the sedative activities of pramipexole.


propoxyphene may increase the sedative activities of Rotigotine.


Pizotifen may increase the sedative activities of ropinirole.


prazepam may increase the sedative activities of pramipexole.


bupivacaine may increase the sedative activities of pramipexole.


imipramine may increase the sedative activities of Rotigotine.


Ramelteon may increase the sedative activities of METYROSINE.


Desloratadine may increase the sedative activities of METYROSINE.


thiopental may increase the sedative activities of pramipexole.


METAXALONE may increase the sedative activities of Rotigotine.


brimonidine may increase the sedative activities of pramipexole.


amobarbital may increase the sedative activities of METYROSINE.


maprotiline may increase the sedative activities of ropinirole.


Ketobemidone may increase the sedative activities of METYROSINE.


ondansetron may increase the sedative activities of pramipexole.


clonazepam may increase the sedative activities of ropinirole.


TETRABENAZINE may increase the sedative activities of pramipexole.


Propoxycaine may increase the sedative activities of METYROSINE.


felbamate may increase the sedative activities of Rotigotine.


vigabatrin may increase the sedative activities of METYROSINE.


Difenoxin may increase the sedative activities of Rotigotine.


bromazepam may increase the sedative activities of pramipexole.


prilocaine may increase the sedative activities of METYROSINE.


Difenoxin may increase the sedative activities of METYROSINE.


Aceprometazine may increase the sedative activities of pramipexole.


clonidine may increase the sedative activities of ropinirole.


risperidone may increase the sedative activities of METYROSINE.


buprenorphine may increase the sedative activities of METYROSINE.


brotizolam may increase the sedative activities of METYROSINE.


ketamine may increase the sedative activities of pramipexole.


chlorpheniramine may increase the sedative activities of METYROSINE.


Levobupivacaine may increase the sedative activities of Rotigotine.


diazepam may increase the sedative activities of ropinirole.


temazepam may increase the sedative activities of METYROSINE.


topiramate may increase the sedative activities of ropinirole.


Pizotifen may increase the sedative activities of pramipexole.


Paliperidone may increase the sedative activities of METYROSINE.


azelastine may increase the sedative activities of METYROSINE.


clonidine may increase the sedative activities of pramipexole.


CYCLIZINE may increase the sedative activities of Rotigotine.


oxycodone may increase the sedative activities of METYROSINE.


amisulpride may increase the sedative activities of Rotigotine.


proparacaine may increase the sedative activities of ropinirole.


Halazepam may increase the sedative activities of pramipexole.


Butethal may increase the sedative activities of ropinirole.


lidocaine may increase the sedative activities of Rotigotine.


morphine may increase the sedative activities of METYROSINE.


phenytoin may increase the sedative activities of pramipexole.


HEROIN may increase the sedative activities of METYROSINE.


hydroxyzine may increase the sedative activities of ropinirole.


butabarbital may increase the sedative activities of ropinirole.


Etomidate may increase the sedative activities of pramipexole.


amitriptyline may increase the sedative activities of ropinirole.


buprenorphine may increase the sedative activities of ropinirole.


trifluoperazine may increase the sedative activities of pramipexole.


sevoflurane may increase the sedative activities of Rotigotine.


pentobarbital may increase the sedative activities of ropinirole.


GUANFACINE may increase the sedative activities of pramipexole.


hydromorphone may increase the sedative activities of Rotigotine.


MAGNESIUM SULFATE may increase the sedative activities of METYROSINE.


prazepam may increase the sedative activities of Rotigotine.


triflupromazine may increase the sedative activities of ropinirole.


zotepine may increase the sedative activities of ropinirole.


haloperidol may increase the sedative activities of ropinirole.


methadone may increase the sedative activities of pramipexole.


dibucaine may increase the sedative activities of pramipexole.


Difenoxin may increase the sedative activities of ropinirole.


Mephobarbital may increase the sedative activities of Rotigotine.


benzyl alcohol may increase the sedative activities of pramipexole.


meprobamate may increase the sedative activities of pramipexole.


ethotoin may increase the sedative activities of METYROSINE.


MOLINDONE may increase the sedative activities of pramipexole.


droperidol may increase the sedative activities of Rotigotine.


ethchlorvynol may increase the sedative activities of ropinirole.


Agomelatine may increase the sedative activities of pramipexole.


mesoridazine may increase the sedative activities of ropinirole.


butabarbital may increase the sedative activities of Rotigotine.


thiothixene may increase the sedative activities of pramipexole.


efavirenz may increase the sedative activities of METYROSINE.


methocarbamol may increase the sedative activities of Rotigotine.


Fencamfamin may increase the sedative activities of Rotigotine.


zaleplon may increase the sedative activities of Rotigotine.


mepivacaine may increase the sedative activities of METYROSINE.


Normethadone may increase the sedative activities of METYROSINE.


triazolam may increase the sedative activities of ropinirole.


Normethadone may increase the sedative activities of ropinirole.


thiothixene may increase the sedative activities of Rotigotine.


Flibanserin may increase the sedative activities of METYROSINE.


enflurane may increase the sedative activities of pramipexole.


Pipamperone may increase the sedative activities of METYROSINE.


Tramadol may increase the sedative activities of Rotigotine.


Retigabine may increase the sedative activities of ropinirole.


Asenapine may increase the sedative activities of METYROSINE.


zonisamide may increase the sedative activities of METYROSINE.


Ropivacaine may increase the sedative activities of METYROSINE.


FLUPHENAZINE may increase the sedative activities of METYROSINE.


Iloperidone may increase the sedative activities of Rotigotine.


VORTIOXETINE may increase the sedative activities of METYROSINE.


trazodone may increase the sedative activities of ropinirole.


Difenoxin may increase the sedative activities of pramipexole.


carisoprodol may increase the sedative activities of ropinirole.


vigabatrin may increase the sedative activities of ropinirole.


Tramadol may increase the sedative activities of pramipexole.


Pipotiazine may increase the sedative activities of ropinirole.


Flibanserin may increase the sedative activities of Rotigotine.


tiagabine may increase the sedative activities of pramipexole.


Levomepromazine may increase the sedative activities of pramipexole.


oxprenolol may increase the sedative activities of ropinirole.


cocaine may increase the sedative activities of ropinirole.


benzocaine may increase the sedative activities of pramipexole.


Ropivacaine may increase the sedative activities of Rotigotine.


butalbital may increase the sedative activities of METYROSINE.


lidocaine may increase the sedative activities of ropinirole.


clemastine may increase the sedative activities of pramipexole.


nalbuphine may increase the sedative activities of Rotigotine.


codeine may increase the sedative activities of METYROSINE.


The risk or severity of QTc prolongation can be increased when toremifene is combined with cisapride.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with ELIGLUSTAT.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with arsenic trioxide.


The risk or severity of QTc prolongation can be increased when hydroxychloroquine is combined with Artemether.


The risk or severity of QTc prolongation can be increased when domperidone is combined with Iloperidone.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with propofol.


The risk or severity of QTc prolongation can be increased when cisapride is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when sotalol is combined with Flupentixol.


The risk or severity of QTc prolongation can be increased when fluoxetine is combined with arsenic trioxide.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Salbutamol.


The risk or severity of QTc prolongation can be increased when sotalol is combined with TETRABENAZINE.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with arsenic trioxide.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with prochlorperazine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with SULFADOXINE.


The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when arsenic trioxide is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when Asenapine is combined with ELIGLUSTAT.


The risk or severity of QTc prolongation can be increased when Quinine is combined with Paliperidone.


The risk or severity of QTc prolongation can be increased when sotalol is combined with quinidine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with REMIFENTANIL.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with tofisopam.


The risk or severity of QTc prolongation can be increased when pimozide is combined with Artemether.


The risk or severity of QTc prolongation can be increased when toremifene is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with pentazocine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Flupentixol.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with terbutaline.


The risk or severity of QTc prolongation can be increased when PROCAINAMIDE is combined with Zuclopenthixol.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with fleroxacin.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with L-tryptophan.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with astemizole.


The risk or severity of QTc prolongation can be increased when sotalol is combined with Zuclopenthixol.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with ELIGLUSTAT.


The risk or severity of QTc prolongation can be increased when sotalol is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with EFINACONAZOLE.


The risk or severity of QTc prolongation can be increased when Escitalopram is combined with domperidone.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with moclobemide.


The risk or severity of QTc prolongation can be increased when fluoxetine is combined with toremifene.


The risk or severity of QTc prolongation can be increased when arsenic trioxide is combined with Paliperidone.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with sotalol.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pefloxacin.


The risk or severity of QTc prolongation can be increased when toremifene is combined with Paliperidone.


The risk or severity of QTc prolongation can be increased when trimethoprim is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Artemether.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with toremifene.


The risk or severity of QTc prolongation can be increased when cisapride is combined with pimozide.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with sotalol.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with viloxazine.


The risk or severity of QTc prolongation can be increased when sotalol is combined with toremifene.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with Asenapine.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Paliperidone.


The risk or severity of QTc prolongation can be increased when quetiapine is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when mefloquine is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Flupentixol.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with toremifene.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with HEROIN.


The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when toremifene is combined with ELIGLUSTAT.


The risk or severity of QTc prolongation can be increased when cisapride is combined with Iloperidone.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with PROCAINAMIDE.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with quinidine.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with toremifene.


The risk or severity of QTc prolongation can be increased when sotalol is combined with ELIGLUSTAT.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with nalidixic acid.


The risk or severity of QTc prolongation can be increased when arsenic trioxide is combined with Asenapine.


The risk or severity of QTc prolongation can be increased when arsenic trioxide is combined with Dronedarone.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Iloperidone.


The risk or severity of QTc prolongation can be increased when TETRABENAZINE is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when pimozide is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with droperidol.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with PIRBUTEROL.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with sulconazole.


The risk or severity of QTc prolongation can be increased when arsenic trioxide is combined with Nilotinib.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with PROCAINAMIDE.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with lithium ion.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with TETRABENAZINE.


The risk or severity of QTc prolongation can be increased when domperidone is combined with Zuclopenthixol.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with triflupromazine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with flecainide.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Terlipressin.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with norfloxacin.


The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with PROCAINAMIDE.


The risk or severity of QTc prolongation can be increased when toremifene is combined with quinidine.


The risk or severity of QTc prolongation can be increased when Flupentixol is combined with PROCAINAMIDE.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Progabide.


The risk or severity of QTc prolongation can be increased when citalopram is combined with arsenic trioxide.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with domperidone.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with roxithromycin.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with Zuclopenthixol.


The risk or severity of QTc prolongation can be increased when ATOVAQUONE is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with pimozide.


The risk or severity of QTc prolongation can be increased when toremifene is combined with TETRABENAZINE.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Halofantrine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Cyamemazine.


The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Dronedarone.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with Zuclopenthixol.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when toremifene is combined with arsenic trioxide.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Asenapine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with oxiconazole.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with TETRABENAZINE.


The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when toremifene is combined with domperidone.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with fluoxetine.


The risk or severity of QTc prolongation can be increased when toremifene is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Lopinavir.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with mesoridazine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with DIPHENOXYLATE.


The risk or severity of QTc prolongation can be increased when Artesunate is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with sotalol.


The risk or severity of QTc prolongation can be increased when citalopram is combined with sotalol.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ibutilide.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with Flupentixol.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with Iloperidone.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with fluoxetine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with tropisetron.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with pentamidine.


The risk or severity of QTc prolongation can be increased when thioridazine is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with quinidine.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Ibutilide.


The risk or severity of QTc prolongation can be increased when quinidine is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when sotalol is combined with pimozide.


The risk or severity of QTc prolongation can be increased when domperidone is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Escitalopram.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fencamfamin.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Flupentixol.


The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Dronedarone.


The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with amoxapine.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with quetiapine.


The risk or severity of QTc prolongation can be increased when Quinine is combined with pimozide.


The risk or severity of QTc prolongation can be increased when Paliperidone is combined with ELIGLUSTAT.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with pentamidine.


The risk or severity of QTc prolongation can be increased when sotalol is combined with PROCAINAMIDE.


The risk or severity of QTc prolongation can be increased when Quinine is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Paliperidone.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Ibutilide.


The risk or severity of QTc prolongation can be increased when pimozide is combined with ELIGLUSTAT.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with pimozide.


The risk or severity of QTc prolongation can be increased when sotalol is combined with Iloperidone.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with ACETOPHENAZINE.


The risk or severity of QTc prolongation can be increased when trimethoprim is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with pimozide.


The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with ritodrine.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with chloroquine.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with Escitalopram.


The risk or severity of QTc prolongation can be increased when quinidine is combined with Paliperidone.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with cisapride.


The risk or severity of QTc prolongation can be increased when proguanil is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when ATOVAQUONE is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when quinidine is combined with Asenapine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with periciazine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with protriptyline.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with Nilotinib.


The risk or severity of QTc prolongation can be increased when PROCAINAMIDE is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when Quinine is combined with Asenapine.


The risk or severity of QTc prolongation can be increased when Flupentixol is combined with quinidine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with zotepine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with MELPERONE.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with ELIGLUSTAT.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with domperidone.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with ELIGLUSTAT.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with ATOVAQUONE.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with Paliperidone.


The risk or severity of QTc prolongation can be increased when SULFADOXINE is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when arsenic trioxide is combined with TETRABENAZINE.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with enoxacin.


The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Artemether.


The risk or severity of QTc prolongation can be increased when cisapride is combined with Asenapine.


The risk or severity of QTc prolongation can be increased when SULFALENE is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when sotalol is combined with Escitalopram.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with tiapride.


The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with anagrelide.


The risk or severity of QTc prolongation can be increased when cisapride is combined with Flupentixol.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with papaverine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Methadyl acetate.


The risk or severity of QTc prolongation can be increased when sotalol is combined with Nilotinib.


The risk or severity of QTc prolongation can be increased when domperidone is combined with quetiapine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with domperidone.


The risk or severity of QTc prolongation can be increased when PRIMAQUINE is combined with Artemether.


The risk or severity of QTc prolongation can be increased when doxycycline is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pizotifen.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with quinidine.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with probucol.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with cocaine.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with ondansetron.


The risk or severity of QTc prolongation can be increased when toremifene is combined with thioridazine.


The risk or severity of QTc prolongation can be increased when quinidine is combined with arsenic trioxide.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Isoconazole.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with cinoxacin.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Lopinavir.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with butorphanol.


The risk or severity of QTc prolongation can be increased when PROCAINAMIDE is combined with Asenapine.


The risk or severity of QTc prolongation can be increased when arsenic trioxide is combined with Zuclopenthixol.


The risk or severity of QTc prolongation can be increased when Quinine is combined with sotalol.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with arsenic trioxide.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Toloxatone.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with cisapride.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with cilostazol.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Nilotinib.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with sparfloxacin.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with chlorprothixene.


The risk or severity of QTc prolongation can be increased when arsenic trioxide is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with amiodarone.


The risk or severity of QTc prolongation can be increased when Flupentixol is combined with amiodarone.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with isoetharine.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Quinine.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with Quinine.


The risk or severity of QTc prolongation can be increased when cisapride is combined with quinidine.


The risk or severity of QTc prolongation can be increased when toremifene is combined with PROCAINAMIDE.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Butoconazole.


The risk or severity of QTc prolongation can be increased when pimozide is combined with arsenic trioxide.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when sotalol is combined with Lopinavir.


The risk or severity of QTc prolongation can be increased when toremifene is combined with Iloperidone.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Asenapine.


The risk or severity of QTc prolongation can be increased when pyrimethamine is combined with Artemether.


The risk or severity of QTc prolongation can be increased when fluoxetine is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with citalopram.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with thioridazine.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tianeptine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sertaconazole.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pipamperone.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Gemifloxacin.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Quinine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with clotrimazole.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with Ibutilide.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with doxycycline.


The risk or severity of QTc prolongation can be increased when arsenic trioxide is combined with ELIGLUSTAT.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with terconazole.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with quinidine.


The risk or severity of QTc prolongation can be increased when cisapride is combined with arsenic trioxide.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dothiepin.


The risk or severity of QTc prolongation can be increased when cisapride is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with domperidone.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with mesoridazine.


The risk or severity of QTc prolongation can be increased when doxycycline is combined with Artemether.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Levomepromazine.


The risk or severity of QTc prolongation can be increased when toremifene is combined with pimozide.


The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Nilotinib.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with domperidone.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Dronedarone.


The risk or severity of QTc prolongation can be increased when SULFADOXINE is combined with Artemether.


The risk or severity of QTc prolongation can be increased when sotalol is combined with domperidone.


The risk or severity of QTc prolongation can be increased when arsenic trioxide is combined with Escitalopram.


The risk or severity of QTc prolongation can be increased when quinacrine is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when Asenapine is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with methadone.


The risk or severity of QTc prolongation can be increased when citalopram is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with bepridil.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with thioridazine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tapentadol.


The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with Asenapine.


The risk or severity of QTc prolongation can be increased when domperidone is combined with TETRABENAZINE.


The risk or severity of QTc prolongation can be increased when sotalol is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when hydroxychloroquine is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when citalopram is combined with pimozide.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with quinidine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with levorphanol.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with arsenic trioxide.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dimetacrine.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Dofetilide.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with azithromycin.


The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Lopinavir.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with Lopinavir.


The risk or severity of QTc prolongation can be increased when toremifene is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with DEZOCINE.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Milnacipran.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with formoterol.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with sevoflurane.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with Flupentixol.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Arformoterol.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with MOLINDONE.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with hydroxychloroquine.


The risk or severity of QTc prolongation can be increased when PROCAINAMIDE is combined with pimozide.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Aceprometazine.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with Dronedarone.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with Iloperidone.


The risk or severity of QTc prolongation can be increased when chloroquine is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with amiodarone.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with fluconazole.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with haloperidol.


The risk or severity of QTc prolongation can be increased when cisapride is combined with TETRABENAZINE.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with quetiapine.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with flecainide.


The risk or severity of QTc prolongation can be increased when cisapride is combined with ELIGLUSTAT.


The risk or severity of QTc prolongation can be increased when quinacrine is combined with Artemether.


The risk or severity of QTc prolongation can be increased when quinidine is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when PROCAINAMIDE is combined with Escitalopram.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with droperidol.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with tranylcypromine.


The risk or severity of QTc prolongation can be increased when PRIMAQUINE is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Zuclopenthixol.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with sotalol.


The risk or severity of QTc prolongation can be increased when Flupentixol is combined with ELIGLUSTAT.


The risk or severity of QTc prolongation can be increased when Vandetanib is combined with ELIGLUSTAT.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Agomelatine.


The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Artemether.


The risk or severity of QTc prolongation can be increased when sotalol is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with toremifene.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with 5-hydroxy-L-tryptophan.


The risk or severity of QTc prolongation can be increased when Quinine is combined with Artemether.


The risk or severity of QTc prolongation can be increased when domperidone is combined with Asenapine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Levomepromazine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with PROCAINAMIDE.


The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Asenapine.


The risk or severity of QTc prolongation can be increased when arsenic trioxide is combined with Iloperidone.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Escitalopram.


The risk or severity of QTc prolongation can be increased when sotalol is combined with Asenapine.


The risk or severity of QTc prolongation can be increased when toremifene is combined with Asenapine.


The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when proguanil is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with HEXOPRENALINE.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with bifonazole.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with anagrelide.


The risk or severity of QTc prolongation can be increased when mefloquine is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when cisapride is combined with Paliperidone.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with isocarboxazid.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with Ibutilide.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Iloperidone.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Escitalopram.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with sotalol.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with josamycin.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with arsenic trioxide.


The risk or severity of QTc prolongation can be increased when toremifene is combined with Zuclopenthixol.


The risk or severity of QTc prolongation can be increased when Flupentixol is combined with arsenic trioxide.


The risk or severity of QTc prolongation can be increased when PROCAINAMIDE is combined with quetiapine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Phenelzine.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with fluoxetine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Normethadone.


The risk or severity of QTc prolongation can be increased when citalopram is combined with Ibutilide.


The risk or severity of QTc prolongation can be increased when domperidone is combined with Paliperidone.


The risk or severity of QTc prolongation can be increased when pimozide is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with FLUPHENAZINE.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with oxaliplatin.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artesunate.


The risk or severity of QTc prolongation can be increased when SULFALENE is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fluspirilene.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with sulpiride.


The risk or severity of QTc prolongation can be increased when amodiaquine is combined with Artemether.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with cisapride.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with ROSOXACIN.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with metaproterenol.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with cisapride.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with citalopram.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with quetiapine.


The risk or severity of QTc prolongation can be increased when PROCAINAMIDE is combined with TETRABENAZINE.


The risk or severity of QTc prolongation can be increased when disopyramide is combined with Paliperidone.


The risk or severity of QTc prolongation can be increased when cisapride is combined with Escitalopram.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with PROCAINAMIDE.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with paroxetine.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with disopyramide.


The risk or severity of QTc prolongation can be increased when Quinine is combined with Flupentixol.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with thioridazine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with sulpiride.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with ciprofloxacin.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with amisulpride.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when TETRABENAZINE is combined with Vemurafenib.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with PROCAINAMIDE.


The risk or severity of QTc prolongation can be increased when Quinine is combined with toremifene.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with TETRABENAZINE.


The risk or severity of QTc prolongation can be increased when chloroquine is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with loxapine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Remoxipride.


The risk or severity of QTc prolongation can be increased when cisapride is combined with domperidone.


The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Ibutilide.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with disopyramide.


The risk or severity of QTc prolongation can be increased when pimozide is combined with domperidone.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with thioridazine.


The risk or severity of QTc prolongation can be increased when cisapride is combined with quetiapine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with PROCATEROL.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with LEVOFLOXACIN.


The risk or severity of QTc prolongation can be increased when Quinine is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Gatifloxacin.


The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Nilotinib.


The risk or severity of QTc prolongation can be increased when arsenic trioxide is combined with Artemether.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with donepezil.


The risk or severity of QTc prolongation can be increased when toremifene is combined with Flupentixol.


The risk or severity of QTc prolongation can be increased when pyrimethamine is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with thioridazine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with nalbuphine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with SULFALENE.


The risk or severity of QTc prolongation can be increased when amodiaquine is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with moxifloxacin.


The risk or severity of QTc prolongation can be increased when PROCAINAMIDE is combined with Iloperidone.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with erythromycin.


The risk or severity of QTc prolongation can be increased when arsenic trioxide is combined with Lopinavir.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Zuclopenthixol.


The risk or severity of QTc prolongation can be increased when toremifene is combined with Escitalopram.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Zuclopenthixol.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with sotalol.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with domperidone.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Thioproperazine.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Paliperidone.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Isavuconazole.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with pyrimethamine.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with TETRABENAZINE.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Vorinostat.


The risk or severity of QTc prolongation can be increased when Ibutilide is combined with cisapride.


The risk or severity of QTc prolongation can be increased when cisapride is combined with PROCAINAMIDE.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with fluconazole.


The risk or severity of QTc prolongation can be increased when sotalol is combined with cisapride.


The risk or severity of QTc prolongation can be increased when Artesunate is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when Asenapine is combined with Lumefantrine.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with pimozide.


The risk or severity of QTc prolongation can be increased when amiodarone is combined with Paliperidone.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pirlindole.


The risk or severity of QTc prolongation can be increased when PROCAINAMIDE is combined with domperidone.


The risk or severity of QTc prolongation can be increased when PROCAINAMIDE is combined with Paliperidone.


The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with arsenic trioxide.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with anagrelide.


The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Gatifloxacin.


The risk or severity of QTc prolongation can be increased when PROCAINAMIDE is combined with arsenic trioxide.


The risk or severity of QTc prolongation can be increased when cisapride is combined with Zuclopenthixol.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with Vandetanib.


The risk or severity of QTc prolongation can be increased when toremifene is combined with quetiapine.


The risk or severity of QTc prolongation can be increased when anagrelide is combined with disopyramide.


The risk or severity of QTc prolongation can be increased when Quinine is combined with arsenic trioxide.


The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Trovafloxacin.


The risk or severity of QTc prolongation can be increased when arsenic trioxide is combined with domperidone.


The risk or severity of QTc prolongation can be increased when Flupentixol is combined with domperidone.


The risk or severity of QTc prolongation can be increased when Dofetilide is combined with quetiapine.


Nelarabine may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of Ruxolitinib.


5-azacytidine may increase the immunosuppressive activities of Tofacitinib.


ifosfamide may increase the immunosuppressive activities of Tofacitinib.


cytarabine may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of rapamycin.


lomustine may increase the immunosuppressive activities of Fingolimod.


Tofacitinib may increase the immunosuppressive activities of Fingolimod.


triamcinolone may increase the immunosuppressive activities of Fingolimod.


Panobinostat may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of actinomycin D.


mechlorethamine may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of Pemetrexed.


tretinoin may increase the immunosuppressive activities of Tofacitinib.


vincristine may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of Lenalidomide.


Roflumilast may increase the immunosuppressive activities of irinotecan.


temozolomide may increase the immunosuppressive activities of Fingolimod.


cyclosporin A may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of Panobinostat.


Roflumilast may increase the immunosuppressive activities of BENZNIDAZOLE.


busulfan may increase the immunosuppressive activities of Fingolimod.


Stepronin may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of lomustine.


altretamine may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of mitoxantrone.


Roflumilast may increase the immunosuppressive activities of vinorelbine.


DEFLAZACORT may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of Fludarabine.


vinorelbine may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of DEFLAZACORT.


Roflumilast may increase the immunosuppressive activities of amsacrine.


carboplatin may increase the immunosuppressive activities of Fingolimod.


procarbazine may increase the immunosuppressive activities of Tofacitinib.


thioguanine may increase the immunosuppressive activities of Fingolimod.


mitoxantrone may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of cytarabine.


5-Fluorouracil may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of methotrexate.


IMIQUIMOD may increase the immunosuppressive activities of Tofacitinib.


oxaliplatin may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of Ibrutinib.


dexamethasone may increase the immunosuppressive activities of Fingolimod.


Nilotinib may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of cyclosporin A.


Apremilast may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of mechlorethamine.


Pemetrexed may increase the immunosuppressive activities of Tofacitinib.


CAPECITABINE may increase the immunosuppressive activities of Tofacitinib.


Icatibant may increase the immunosuppressive activities of Tofacitinib.


betamethasone may increase the immunosuppressive activities of Tofacitinib.


Fludarabine may increase the immunosuppressive activities of Tofacitinib.


Pralatrexate may increase the immunosuppressive activities of Fingolimod.


Pazopanib may increase the immunosuppressive activities of Tofacitinib.


etoposide may increase the immunosuppressive activities of Fingolimod.


Idelalisib may increase the immunosuppressive activities of Fingolimod.


temozolomide may increase the immunosuppressive activities of Tofacitinib.


busulfan may increase the immunosuppressive activities of Tofacitinib.


Ruxolitinib may increase the immunosuppressive activities of Fingolimod.


melphalan may increase the immunosuppressive activities of Fingolimod.


Sorafenib may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of ifosfamide.


Nilotinib may increase the immunosuppressive activities of Tofacitinib.


CAPECITABINE may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of Sorafenib.


Imatinib may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of IDARUBICIN.


Roflumilast may increase the immunosuppressive activities of Dimethyl fumarate.


Roflumilast may increase the immunosuppressive activities of Pralatrexate.


Roflumilast may increase the immunosuppressive activities of pentostatin.


daunorubicin may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of Fingolimod.


teniposide may increase the immunosuppressive activities of Tofacitinib.


Teriflunomide may increase the immunosuppressive activities of Tofacitinib.


prednisone may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of methylprednisolone.


Roflumilast may increase the immunosuppressive activities of carboplatin.


Roflumilast may increase the immunosuppressive activities of Pomalidomide.


DEFLAZACORT may increase the immunosuppressive activities of Tofacitinib.


budesonide may increase the immunosuppressive activities of Tofacitinib.


fludrocortisone may increase the immunosuppressive activities of Tofacitinib.


PIRFENIDONE may increase the immunosuppressive activities of Fingolimod.


cyclophosphamide may increase the immunosuppressive activities of cyclosporin A.


azathioprine may increase the immunosuppressive activities of Fingolimod.


actinomycin D may increase the immunosuppressive activities of Tofacitinib.


mitomycin C may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of Teriflunomide.


Roflumilast may increase the immunosuppressive activities of Sunitinib.


cisplatin may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of streptozocin.


Roflumilast may increase the immunosuppressive activities of triamcinolone.


Roflumilast may increase the immunosuppressive activities of Pazopanib.


mycophenolate mofetil may increase the immunosuppressive activities of Tofacitinib.


carmustine may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of daunorubicin.


lomustine may increase the immunosuppressive activities of Tofacitinib.


hydroxyurea may increase the immunosuppressive activities of Tofacitinib.


Dimethyl fumarate may increase the immunosuppressive activities of Tofacitinib.


Cladribine may increase the immunosuppressive activities of Fingolimod.


Ibrutinib may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of Cladribine.


amsacrine may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of vindesine.


Roflumilast may increase the immunosuppressive activities of vincristine.


doxorubicin may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of mitomycin C.


Pazopanib may increase the immunosuppressive activities of Fingolimod.


actinomycin D may increase the immunosuppressive activities of Fingolimod.


Apremilast may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of altretamine.


vinblastine may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of Palbociclib.


hydrocortisone may increase the immunosuppressive activities of Tofacitinib.


rapamycin may increase the immunosuppressive activities of Fingolimod.


Epirubicin may increase the immunosuppressive activities of Tofacitinib.


5-Fluorouracil may increase the immunosuppressive activities of Fingolimod.


mechlorethamine may increase the immunosuppressive activities of Tofacitinib.


L-phenylalanine may increase the immunosuppressive activities of Fingolimod.


vinblastine may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of Tofacitinib.


Temsirolimus may increase the immunosuppressive activities of Tofacitinib.


tretinoin may increase the immunosuppressive activities of Fingolimod.


thiotepa may increase the immunosuppressive activities of Fingolimod.


gemcitabine may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of Dasatinib.


Icatibant may increase the immunosuppressive activities of Fingolimod.


Vilanterol may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of Clofarabine.


Roflumilast may increase the immunosuppressive activities of glimepiride.


rapamycin may increase the immunosuppressive activities of Tofacitinib.


docetaxel may increase the immunosuppressive activities of Fingolimod.


Panobinostat may increase the immunosuppressive activities of Fingolimod.


hydroxyurea may increase the immunosuppressive activities of Fingolimod.


docetaxel may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of cyclophosphamide.


Roflumilast may increase the immunosuppressive activities of busulfan.


altretamine may increase the immunosuppressive activities of Tofacitinib.


streptozocin may increase the immunosuppressive activities of Fingolimod.


pentostatin may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of Temsirolimus.


Roflumilast may increase the immunosuppressive activities of hydroxyurea.


Temsirolimus may increase the immunosuppressive activities of Fingolimod.


mitomycin C may increase the immunosuppressive activities of Fingolimod.


mitoxantrone may increase the immunosuppressive activities of Fingolimod.


ifosfamide may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of Pimecrolimus.


BENZNIDAZOLE may increase the immunosuppressive activities of Tofacitinib.


Sunitinib may increase the immunosuppressive activities of Tofacitinib.


cytarabine may increase the immunosuppressive activities of Tofacitinib.


Pimecrolimus may increase the immunosuppressive activities of Fingolimod.


CORTISONE ACETATE may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of Idelalisib.


tacrolimus may increase the immunosuppressive activities of Fingolimod.


mycophenolate mofetil may increase the immunosuppressive activities of Fingolimod.


Pomalidomide may increase the immunosuppressive activities of Tofacitinib.


carboplatin may increase the immunosuppressive activities of Tofacitinib.


glimepiride may increase the immunosuppressive activities of Tofacitinib.


Dimethyl fumarate may increase the immunosuppressive activities of Fingolimod.


dexamethasone may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of IMIQUIMOD.


streptozocin may increase the immunosuppressive activities of Tofacitinib.


Palbociclib may increase the immunosuppressive activities of Fingolimod.


Lenalidomide may increase the immunosuppressive activities of Fingolimod.


Fludarabine may increase the immunosuppressive activities of Fingolimod.


chlorambucil may increase the immunosuppressive activities of Fingolimod.


cyclophosphamide may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of Nilotinib.


IMIQUIMOD may increase the immunosuppressive activities of Fingolimod.


fludrocortisone may increase the immunosuppressive activities of Fingolimod.


Cladribine may increase the immunosuppressive activities of Tofacitinib.


hydrocortisone may increase the immunosuppressive activities of Fingolimod.


IDARUBICIN may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of docetaxel.


tacrolimus may increase the immunosuppressive activities of Tofacitinib.


6-Mercaptopurine may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of mycophenolate mofetil.


CABAZITAXEL may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of floxuridine.


methotrexate may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of oxaliplatin.


Roflumilast may increase the immunosuppressive activities of topotecan.


Roflumilast may increase the immunosuppressive activities of Epirubicin.


Roflumilast may increase the immunosuppressive activities of teniposide.


Roflumilast may increase the immunosuppressive activities of betamethasone.


Roflumilast may increase the immunosuppressive activities of fludrocortisone.


BENZNIDAZOLE may increase the immunosuppressive activities of Fingolimod.


Epirubicin may increase the immunosuppressive activities of Fingolimod.


Sunitinib may increase the immunosuppressive activities of Fingolimod.


gemcitabine may increase the immunosuppressive activities of Fingolimod.


L-phenylalanine may increase the immunosuppressive activities of Tofacitinib.


mycophenolic acid may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of prednisone.


bleomycin may increase the immunosuppressive activities of Fingolimod.


pentostatin may increase the immunosuppressive activities of Fingolimod.


estramustine may increase the immunosuppressive activities of Fingolimod.


Pomalidomide may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of Stepronin.


Roflumilast may increase the immunosuppressive activities of 5-azacytidine.


5-azacytidine may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of Imatinib.


mycophenolic acid may increase the immunosuppressive activities of Fingolimod.


Roflumilast may increase the immunosuppressive activities of 6-Mercaptopurine.


vindesine may increase the immunosuppressive activities of Fingolimod.


triamcinolone may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of tretinoin.


daunorubicin may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of 5-Fluorouracil.


Roflumilast may increase the immunosuppressive activities of cisplatin.


procarbazine may increase the immunosuppressive activities of Fingolimod.


thalidomide may increase the immunosuppressive activities of Fingolimod.


Nelarabine may increase the immunosuppressive activities of Tofacitinib.


cyclosporin A may increase the immunosuppressive activities of Tofacitinib.


Roflumilast may increase the immunosuppressive activities of thioguanine.


Roflumilast may increase the immunosuppressive activities of mycophenolic acid.